Endovascular Treatment of Acute Ischemic Stroke May Be Safely Performed With No Time Window Limit in Appropriately Selected Patients

Background and Purpose— The traditional time window for acute ischemic stroke intra-arterial therapy (IAT) is <6 hours, which is based on pharmacological thrombolysis without penumbral imaging. This study was conducted to determine the safety of patient selection for IAT based on perfusion mismatch rather than time. Methods— A cohort of consecutive patients treated with IAT was identified by database review. Patients were selected for IAT based on the presence of perfusion mismatch using CT perfusion or MRI regardless of stroke duration. Thrombolytics were minimized after 6 hours in favor of mechanical embolectomy or angioplasty±stenting. Outcomes (National Institutes of Health Stroke Scale, modified Rankin Scale) were assessed by independent examiners. A multivariate analysis was performed to compare those treated <6 hours (early) with those treated >6 hours (late). Results— Fifty-five patients (mean National Institutes of Health Stroke Scale=19.7±5.7) were treated, 34 early and 21 late, with mean time-to-intervention of 3.4±1.6 hours and 18.6±16.0 hours, respectively. Thrombolysis In Myocardial Ischemia 2 or 3 recanalization was achieved in 82.8% early and 85.7% late patients (P=1.0). Intracerebral hemorrhage occurred in 25.5% overall, but symptomatic intracerebral hemorrhage occurred in 8.8% of the early and 9.5% of the late patients (P=1.0). Thirty-day mortality was similar (29.4% versus 23.8%, P=0.650). At 3 months, 41.2% and 42.9%, respectively, achieved a modified Rankin Scale ≤2 (P=0.902). Only presenting National Institutes of Health Stroke Scale was a predictor of modified Rankin Scale ≤2 (OR 0.794[95% CI 0.68 to 0.92], P=0.009) and death (adjusted OR 1.29[95% CI 1.04 to 1.59], P=0.019). Conclusions— In appropriately selected patients, IAT for acute ischemic stroke can be performed safely regardless of stroke duration. The concept of an acute ischemic stroke treatment window for IAT should be re-evaluated with a clinical trial selecting patients with perfusion mismatch.

[1]  Penumbra Pivotal Stroke Trial Investigators.  The Penumbra Pivotal Stroke Trial: Safety and Effectiveness of a New Generation of Mechanical Devices for Clot Removal in Intracranial Large Vessel Occlusive Disease , 2009, Stroke.

[2]  L. Wechsler,et al.  Mechanical Approaches Combined With Intra-Arterial Pharmacological Therapy Are Associated With Higher Recanalization Rates Than Either Intervention Alone in Revascularization of Acute Carotid Terminus Occlusion , 2009, Stroke.

[3]  N. Vora,et al.  Safety of Angioplasty and Stenting Without Thrombolysis for the Treatment of Early Ischemic Stroke , 2009, Journal of neuroimaging : official journal of the American Society of Neuroimaging.

[4]  M. Kaste,et al.  Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. , 2008, The New England journal of medicine.

[5]  H. Lutsep,et al.  Mechanical Thrombectomy for Acute Ischemic Stroke: Final Results of the Multi MERCI Trial , 2008, Stroke.

[6]  R. Koehler,et al.  Delayed Tolerance With Repetitive Transient Focal Ischemic Preconditioning in the Mouse , 2008, Stroke.

[7]  N. Grigoriadis,et al.  Clinically successful late recanalization of basilar artery occlusion in childhood: What are the odds? Case report and review of the literature , 2007, Journal of the Neurological Sciences.

[8]  L. Wechsler,et al.  Factors Predicting Hemorrhagic Complications after Multimodal Reperfusion Therapy for Acute Ischemic Stroke , 2007, American Journal of Neuroradiology.

[9]  H. Yonas,et al.  Reduced Pretreatment Ipsilateral Middle Cerebral Artery Cerebral Blood Flow Is Predictive of Symptomatic Hemorrhage Post–Intra-Arterial Thrombolysis in Patients With Middle Cerebral Artery Occlusion , 2006, Stroke.

[10]  K. Furie,et al.  Association between tPA therapy and raised early matrix metalloproteinase-9 in acute stroke , 2006, Neurology.

[11]  L. Wechsler,et al.  Multimodal Reperfusion Therapy for Acute Ischemic Stroke: Factors Predicting Vessel Recanalization , 2006, Stroke.

[12]  Reto Meuli,et al.  Perfusion-CT Assessment of Infarct Core and Penumbra: Receiver Operating Characteristic Curve Analysis in 130 Patients Suspected of Acute Hemispheric Stroke , 2006, Stroke.

[13]  D. Krieger,et al.  Multimodal Therapy for the Treatment of Severe Ischemic Stroke Combining GPIIb/IIIa Antagonists and Angioplasty After Failure of Thrombolysis , 2005, Stroke.

[14]  H. Diener,et al.  Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial , 2004, The Lancet.

[15]  S. Nakano,et al.  Direct Percutaneous Transluminal Angioplasty for Acute Middle Cerebral Artery Trunk Occlusion: An Alternative Option to Intra-arterial Thrombolysis , 2002, Stroke.

[16]  B. Rosen,et al.  Rapid Breakdown of Microvascular Barriers and Subsequent Hemorrhagic Transformation After Delayed Recombinant Tissue Plasminogen Activator Treatment in a Rat Embolic Stroke Model , 2002, Stroke.

[17]  Erich Bluhmki,et al.  Risk Factors for Severe Hemorrhagic Transformation in Ischemic Stroke Patients Treated With Recombinant Tissue Plasminogen Activator: A Secondary Analysis of the European-Australasian Acute Stroke Study (ECASS II) , 2001, Stroke.

[18]  R. Higashida,et al.  Intra-arterial Prourokinase for Acute Ischemic Stroke: The PROACT II Study: A Randomized Controlled Trial , 1999 .

[19]  D. Lackland,et al.  The geographic variation in stroke incidence in two areas of the southeastern stroke belt: the Anderson and Pee Dee Stroke Study. , 1998, Stroke.

[20]  W. Hacke,et al.  Thrombolytic therapy of acute basilar artery occlusion. Variables affecting recanalization and outcome. , 1996, Stroke.

[21]  Joseph P. Broderick,et al.  Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. , 1995 .

[22]  Nirds,et al.  Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group , 1995 .

[23]  R. Sacco,et al.  Race-ethnicity and determinants of intracranial atherosclerotic cerebral infarction. The Northern Manhattan Stroke Study. , 1995, Stroke.

[24]  B. Coull,et al.  Safety and efficacy of delayed intraarterial urokinase therapy with mechanical clot disruption for thromboembolic stroke. , 1994, AJNR. American journal of neuroradiology.

[25]  H. S. Mueller,et al.  The Thrombolysis in Myocardial Infarction (TIMI) trial. Phase I findings. , 1985, The New England journal of medicine.